Figure 1.

First-line treatment and testing patterns by label change period. ^aPD-L1 status was determined using recorded results from Dako 22C3 assays, Ventana SP142 assays, and written lab interpretations (positive or negative). Patients with results on any of these indicators were classified as tested. We classified patients as PD-L1 positive if they had a combined positive score of ≥10%, percent staining ≥5%, or positive lab within 30 days after or any time prior to treatment initiation. Patients were classified as negative if they had at least 1 PD-L1 indicator on record (from any of the 3 fields) and no positive tests. ICI = immune checkpoint inhibitors; PD-L1 = programmed cell death protein ligand-1.